Combination Therapy with Trastuzumab and Niraparib: Quantifying Early Proliferative Alterations in HER2+ Breast Cancer Models.

ABSTRACT: HER2-targeted treatments have improved survival rates in HER2+ breast cancer patients, yet poor responsiveness remains a major clinical obstacle. Recently, HER2+ breast cancer cells, both resistant and responsive to HER2-targeted therapies, have demonstrated sensitivity to poly-(ADP-ribose) polymerase (PARP) inhibition, independent of DNA repair deficiencies. This study seeks to describe biological factors that precede cell viability changes in response to the combination of trastuzumab and PARP inhibition. Treatment response was evaluated in HER2+ and HER2- breast cancer cells. Further, we evaluated the utility of 3'-Deoxy-3'-[¹⁸F]-fluorothymidine positron emission tomography ([¹⁸F]FLT-PET) imaging for early response assessment in a HER2+ patient derived xenograft (P

SUBMITTER: Mansur A 

PROVIDER: S-EPMC10452700 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature